Venous Diseases Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2022-2031

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Venous Diseases Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Porter's Five Force Analysis

5. Key Insights

• 5.1. Regulatory Scenario by Region/globally
• 5.2. Technological Advancements
• 5.3. Pipeline Analysis
• 5.4. Key Mergers & Acquisitions
• 5.5. Disease Prevalence & Incidence Rate globally with key countries
• 5.6. Reimbursement Scenario by Region/globally

6. Global Venous Diseases Treatment Analysis and Forecast, by Treatment Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Treatment, 2017-2031
  • 6.3.1. Surgeries
    • 6.3.1.1. Angioplasty or Stenting
    • 6.3.1.2. Vein Ligation and Stripping
    • 6.3.1.3. Vena Cava Filter
    • 6.3.1.4. Ambulatory Phlebectomy
    • 6.3.1.5. Others
  • 6.3.2. Therapies
    • 6.3.2.1. Sclerotherapy
    • 6.3.2.2. Radiofrequency Ablation Therapy
    • 6.3.2.3. Laser Treatment
• 6.4. Market Attractiveness Analysis, by Treatment

7. Global Venous Diseases Treatment Analysis and Forecast, by Disease Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Disease Type, 2017-2031
  • 7.3.1. Deep-vein Thrombophlebitis
  • 7.3.2. Varicose Veins
  • 7.3.3. Superficial Thrombophlebitis
  • 7.3.4. Chronic Venous Insufficiency
  • 7.3.5. Venous Ulcers
  • 7.3.6. Others
• 7.4. Market Attractiveness Analysis, by Disease Type

8. Global Venous Diseases Treatment Analysis and Forecast, by Product Type

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by Product Type, 2017-2031
  • 8.3.1. Ablation Devices
  • 8.3.2. Venous Stents
  • 8.3.3. Venous Closure Treatments
  • 8.3.4. Sclerotherapy Injection
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis, by Product Type

9. Global Venous Diseases Treatment Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Ambulatory centers
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Venous Diseases Treatment Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness Analysis, by Region

11. North America Venous Diseases Treatment Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Treatment, 2017-2031
  • 11.2.1. Surgeries
    • 11.2.1.1. Angioplasty or Stenting
    • 11.2.1.2. Vein Ligation and Stripping
    • 11.2.1.3. Vena Cava Filter
    • 11.2.1.4. Ambulatory Phlebectomy
    • 11.2.1.5. Others
  • 11.2.2. Therapies
    • 11.2.2.1. Sclerotherapy
    • 11.2.2.2. Radiofrequency Ablation Therapy
    • 11.2.2.3. Laser Treatment
• 11.3. Market Value Forecast, by Disease Type, 2017-2031
  • 11.3.1. Deep-vein Thrombophlebitis
  • 11.3.2. Varicose Veins
  • 11.3.3. Superficial Thrombophlebitis
  • 11.3.4. Chronic Venous Insufficiency
  • 11.3.5. Venous Ulcers
  • 11.3.6. Others
• 11.4. Market Value Forecast, by Product Type, 2017-2031
  • 11.4.1. Ablation Devices
  • 11.4.2. Venous Stents
  • 11.4.3. Venous Closure Treatments
  • 11.4.4. Sclerotherapy Injection
  • 11.4.5. Others
• 11.5. Market Value Forecast, by End-user, 2017-2031
  • 11.5.1. Hospitals
  • 11.5.2. Clinics
  • 11.5.3. Ambulatory centers
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Treatment
  • 11.7.2. By Disease Type
  • 11.7.3. By Product Type
  • 11.7.4. By End-user
  • 11.7.5. By Country/Sub-region

12. Europe Venous Diseases Treatment Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Treatment, 2017-2031
  • 12.2.1. Surgeries
    • 12.2.1.1. Angioplasty or Stenting
    • 12.2.1.2. Vein Ligation and Stripping
    • 12.2.1.3. VeEnd Use Cava Filter
    • 12.2.1.4. Ambulatory Phlebectomy
    • 12.2.1.5. Others
  • 12.2.2. Therapies
    • 12.2.2.1. Sclerotherapy
    • 12.2.2.2. Radiofrequency Ablation Therapy
    • 12.2.2.3. Laser Treatment
• 12.3. Market Value Forecast, by Disease Type, 2017-2031
  • 12.3.1. Deep-vein Thrombophlebitis
  • 12.3.2. Varicose Veins
  • 12.3.3. Superficial Thrombophlebitis
  • 12.3.4. Chronic Venous Insufficiency
  • 12.3.5. Venous Ulcers
  • 12.3.6. Others
• 12.4. Market Value Forecast, by Product Type, 2017-2031
  • 12.4.1. Ablation Devices
  • 12.4.2. Venous Stents
  • 12.4.3. Venous Closure Treatments
  • 12.4.4. Sclerotherapy Injection
  • 12.4.5. Others
• 12.5. Market Value Forecast, by End-user, 2017-2031
  • 12.5.1. Hospitals
  • 12.5.2. Clinics
  • 12.5.3. Ambulatory centers
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Treatment
  • 12.7.2. By Disease Type
  • 12.7.3. By Product Type
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Venous Diseases Treatment Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Treatment, 2017-2031
  • 13.2.1. Surgeries
    • 13.2.1.1. Angioplasty or Stenting
    • 13.2.1.2. Vein Ligation and Stripping
    • 13.2.1.3. VeEnd Use Cava Filter
    • 13.2.1.4. Ambulatory Phlebectomy
    • 13.2.1.5. Others
  • 13.2.2. Therapies
    • 13.2.2.1. Sclerotherapy
    • 13.2.2.2. Radiofrequency Ablation Therapy
    • 13.2.2.3. Laser Treatment
• 13.3. Market Value Forecast, by Disease Type, 2017-2031
  • 13.3.1. Deep-vein Thrombophlebitis
  • 13.3.2. Varicose Veins
  • 13.3.3. Superficial Thrombophlebitis
  • 13.3.4. Chronic Venous Insufficiency
  • 13.3.5. Venous Ulcers
  • 13.3.6. Others
• 13.4. Market Value Forecast, by Product Type, 2017-2031
  • 13.4.1. Ablation Devices
  • 13.4.2. Venous Stents
  • 13.4.3. Venous Closure Treatments
  • 13.4.4. Sclerotherapy Injection
  • 13.4.5. Others
• 13.5. Market Value Forecast, by End-user, 2017-2031
  • 13.5.1. Hospitals
  • 13.5.2. Clinics
  • 13.5.3. Ambulatory centers
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Treatment
  • 13.7.2. By Disease Type
  • 13.7.3. By Product Type
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Venous Diseases Treatment Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Treatment, 2017-2031
  • 14.2.1. Surgeries
    • 14.2.1.1. Angioplasty or Stenting
    • 14.2.1.2. Vein Ligation and Stripping
    • 14.2.1.3. VeEnd Use Cava Filter
    • 14.2.1.4. Ambulatory Phlebectomy
    • 14.2.1.5. Others
  • 14.2.2. Therapies
    • 14.2.2.1. Sclerotherapy
    • 14.2.2.2. Radiofrequency Ablation Therapy
    • 14.2.2.3. Laser Treatment
• 14.3. Market Value Forecast, by Disease Type, 2017-2031
  • 14.3.1. Deep-vein Thrombophlebitis
  • 14.3.2. Varicose Veins
  • 14.3.3. Superficial Thrombophlebitis
  • 14.3.4. Chronic Venous Insufficiency
  • 14.3.5. Venous Ulcers
  • 14.3.6. Others
• 14.4. Market Value Forecast, by Product Type, 2017-2031
  • 14.4.1. Ablation Devices
  • 14.4.2. Venous Stents
  • 14.4.3. Venous Closure Treatments
  • 14.4.4. Sclerotherapy Injection
  • 14.4.5. Others
• 14.5. Market Value Forecast, by End-user, 2017-2031
  • 14.5.1. Hospitals
  • 14.5.2. Clinics
  • 14.5.3. Ambulatory centers
• 14.6. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Treatment
  • 14.7.2. By Disease Type
  • 14.7.3. By Product Type
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Venous Diseases Treatment Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Treatment, 2017-2031
  • 15.2.1. Surgeries
    • 15.2.1.1. Angioplasty or Stenting
    • 15.2.1.2. Vein Ligation and Stripping
    • 15.2.1.3. VeEnd Use Cava Filter
    • 15.2.1.4. Ambulatory Phlebectomy
    • 15.2.1.5. Others
  • 15.2.2. Therapies
    • 15.2.2.1. Sclerotherapy
    • 15.2.2.2. Radiofrequency Ablation Therapy
    • 15.2.2.3. Laser Treatment
• 15.3. Market Value Forecast, by Disease Type, 2017-2031
  • 15.3.1. Deep-vein Thrombophlebitis
  • 15.3.2. Varicose Veins
  • 15.3.3. Superficial Thrombophlebitis
  • 15.3.4. Chronic Venous Insufficiency
  • 15.3.5. Venous Ulcers
  • 15.3.6. Others
• 15.4. Market Value Forecast, by Product Type, 2017-2031
  • 15.4.1. Ablation Devices
  • 15.4.2. Venous Stents
  • 15.4.3. Venous Closure Treatments
  • 15.4.4. Sclerotherapy Injection
  • 15.4.5. Others
• 15.5. Market Value Forecast, by End-user, 2017-2031
  • 15.5.1. Hospitals
  • 15.5.2. Clinics
  • 15.5.3. Ambulatory centers
• 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

16. Competitive Landscape

• 16.1. Market Player - Competition Matrix (by tier and size of companies)
• 16.2. Market Share Analysis, by Company, 2021
• 16.3. Company Profiles
  • 16.3.1. Zimmer Biomet Holdings, Inc.
    • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.1.2. Company Financials
    • 16.3.1.3. Growth Strategies
    • 16.3.1.4. SWOT Analysis
  • 16.3.2. Medtronic
    • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.2.2. Company Financials
    • 16.3.2.3. Growth Strategies
    • 16.3.2.4. SWOT Analysis
  • 16.3.3. AngioDynamics
    • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.3.2. Company Financials
    • 16.3.3.3. Growth Strategies
    • 16.3.3.4. SWOT Analysis
  • 16.3.4. Alma Lasers
    • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.4.2. Company Financials
    • 16.3.4.3. Growth Strategies
    • 16.3.4.4. SWOT Analysis
  • 16.3.5. Biolitec AG Untere Viaduktgasse
    • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.5.2. Company Financials
    • 16.3.5.3. Growth Strategies
    • 16.3.5.4. SWOT Analysis
  • 16.3.6. Becton, Dickinson and Company
    • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.6.2. Company Financials
    • 16.3.6.3. Growth Strategies
    • 16.3.6.4. SWOT Analysis
  • 16.3.7. Boston Scientific Corporation
    • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.7.2. Company Financials
    • 16.3.7.3. Growth Strategies
    • 16.3.7.4. SWOT Analysis
  • 16.3.8. Abbott Laboratories
    • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.8.2. Company Financials
    • 16.3.8.3. Growth Strategies
    • 16.3.8.4. SWOT Analysis
  • 16.3.9. B. Braun Melsungen AG
    • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.9.2. Company Financials
    • 16.3.9.3. Growth Strategies
    • 16.3.9.4. SWOT Analysis
  • 16.3.10. Teleflex Incorporated
    • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.10.2. Company Financials
    • 16.3.10.3. Growth Strategies
    • 16.3.10.4. SWOT Analysis
  • 16.3.11. Lumenis
    • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.11.2. Company Financials
    • 16.3.11.3. Growth Strategies
    • 16.3.11.4. SWOT Analysis
  • 16.3.12. Philips
    • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 16.3.12.2. Company Financials
    • 16.3.12.3. Growth Strategies
    • 16.3.12.4. SWOT Analysis

List of Tables

• Table 01: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 02: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 03: Global Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 04: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Region, 2017-2031
• Table 06: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country, 2017-2031
• Table 07: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 08: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 09: North America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 10: North America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 11: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
• Table 12: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 13: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 14: Europe Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 15: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 16: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
• Table 17: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 18: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 19: Asia Pacific Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 20: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 21: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 22: India Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 23: India Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 24: India Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 25: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
• Table 26: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 27: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 28: Latin America Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 29: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031
• Table 30: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
• Table 31: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Treatment Type, 2017-2031
• Table 32: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Table 33: Middle East & Africa Venous Diseases Treatment Revenue (US$ Bn) Forecast, by Product Type, 2017-2031
• Table 34: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, by End-use, 2017-2031

List of Figures

• Figure 01: Global Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 02: Global Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 03: Global Venous Diseases Treatment Revenue (US$ Bn), by Surgeries, 2017-2031
• Figure 04: Global Venous Diseases Treatment Revenue (US$ Bn), by Therapies, 2017-2031
• Figure 05: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Disease Type, 2017-2031
• Figure 06: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Product Type, 2017-2031
• Figure 07: Global Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 08: Global Venous Diseases Treatment Attractiveness Analysis, by Angioplasty or Stenting, 2022-2031
• Figure 09: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vein Ligation and stripping, 2017-2031
• Figure 10: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Vena Cava Filter, 2017-2031
• Figure 11: Global Venous Diseases Treatment Value Share Analysis, by Ambulatory Phlebectomy Type, 2021 and 2031
• Figure 12: Global Venous Diseases Treatment Attractiveness Analysis, by Others, 2022-2031
• Figure 13: Global Venous Diseases Treatment Revenue (US$ Bn), by Sclerotherapy, 2017-2031
• Figure 14: Global Venous Diseases Treatment Revenue (US$ Bn), by Laser treatment, 2017-2031
• Figure 15: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Radiofrequency ablation therapy, 2017-2031
• Figure 16: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Varicose Veins 2017-2031
• Figure 17: Global Venous Diseases Treatment Value Share Analysis, by Superficial Thrombophlebitis, 2021 and 2031
• Figure 18: Global Venous Diseases Treatment Attractiveness Analysis, by Deep-vein Thrombophlebitis, 2022-2031
• Figure 19: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Chronic Venous Insufficiency, 2017-2031
• Figure 20: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous ulcers, 2017-2031
• Figure 21: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
• Figure 22: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ablation Devices, 2017-2031
• Figure 23: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Sclerotherapy Injection, 2017-2031
• Figure 24: Global Venous Diseases Treatment Attractiveness Analysis, by Venous Closure Treatments, 2022-2031
• Figure 25: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Venous stents
• Figure 26: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Others, 2017-2031
• Figure 27: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Hospitals, 2017-2031
• Figure 28: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Clinics, 2017-2031
• Figure 29: Global Venous Diseases Treatment Value (US$ Bn) Forecast, by Ambulatory centers, 2017-2031
• Figure 30: Global Venous Diseases Treatment Value Share Analysis, by Region, 2021 and 2031
• Figure 31: Global Venous Diseases Treatment Attractiveness Analysis, by Region, 2022-2031
• Figure 32: North America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
• Figure 33: North America Venous Diseases Treatment Value Share Analysis, by Country, 2021 and 2031
• Figure 34: North America Venous Diseases Treatment Attractiveness Analysis, by Country, 2022-2031
• Figure 35: North America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 37: North America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
• Figure 38: North America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
• Figure 39: North America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
• Figure 40: North America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
• Figure 41: North America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 36: North America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
• Figure 37: Europe Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
• Figure 38: Europe Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 39: Europe Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 40: Europe Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 41: Europe Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 42: Europe Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
• Figure 43: Europe Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
• Figure 44: Europe Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
• Figure 45: Europe Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
• Figure 46: Europe Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 47: Europe Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
• Figure 48: Asia Pacific Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
• Figure 49: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 50: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 51: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 52: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 53: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
• Figure 54: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
• Figure 55: Asia Pacific Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
• Figure 56: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
• Figure 57: Asia Pacific Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 58: Asia Pacific Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
• Figure 59: Latin America Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
• Figure 60: Latin America Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 61: Latin America Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 62: Latin America Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 63: Latin America Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 64: Latin America Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
• Figure 65: Latin America Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
• Figure 66: Latin America Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
• Figure 67: Latin America Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
• Figure 68: Latin America Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 69: Latin America Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
• Figure 70: Middle East & Africa Venous Diseases Treatment Value (US$ Bn) Forecast, 2017-2031
• Figure 71: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 72: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 73: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Treatment Type, 2021 and 2031
• Figure 74: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Treatment Type, 2022-2031
• Figure 75: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Disease Type, 2021 and 2031
• Figure 76: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Disease Type, 2022-2031
• Figure 77: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by Product Type, 2021 and 2031
• Figure 78: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by Product Type, 2022-2031
• Figure 79: Middle East & Africa Venous Diseases Treatment Value Share Analysis, by End-use, 2021 and 2031
• Figure 80: Middle East & Africa Venous Diseases Treatment Attractiveness Analysis, by End-use, 2022-2031
• Figure 81: Company Market Share Analysis, 2021